A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to the standard treatments. It will also learn about the safety of this new combination antibiotic treatment when compared to the standard treatments. The main questions it aims to answer are:
* How well does Arm D treat mycobacterium abscessus pulmonary disease?
* What side effects does Arm D cause when used to treat mycobacterium abscessus pulmonary disease? Researchers will compare Arm D to the current standard of care treatments to see if Arm D treats mycobacterium abscessus pulmonary disease better and if it will cause less side effects.
Participants will:
* Be screened and recruited to the FORMaT adaptive platform trial (NCT04310930)
* Be given Arm D for 4 weeks or standard of care treatments for 6 weeks.
* Be reviewed by the study doctors weekly for checkups and tests.
* Provide respiratory samples (sample coughed up from the chest), respond to quality-of-life questionnaires, have CT lung scans and blood tests.

Start Date01 Apr 2027

Sponsor / Collaborator

The University of Queensland

[+1]

NCT03895567

/ SuspendedPhase 1IIT

A Randomised Crossover Study of the Pharmacokinetics, Safety and Tolerability of Two Rectal Formulations of Ceftriaxone Compared to Parenteral Ceftriaxone, in Healthy Thai Adults.

Phase 1, three-way cross-over, randomised, open label comparison of intravenous versus two rectal dosage forms of ceftriaxone in 37 healthy Thai adults.
The following regimens will be evaluated in random order in all participants:
A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1-hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2-rectodispersible mannitol-based tablet (1 x 500mg)
Possible schedules: ABC, ACB, BAC, BCA, CAB, CBA. Each recipient will receive a single treatment dose of each of the three formulations in an order predetermined by a computer generated randomisation list. This will be a constrained randomization which ensures approximately balanced proportions for all six schedules (either 6 or 7 participants per schedule). There will be 7-28 days washout period between doses. The last follow up visit is 28 (+ 2) days after final dose. Participants lost to follow-up or unevaluable for any reason before completion of pharmacokinetic sampling after the final dose will be replaced at the discretion of the investigators with another participant of the same population, if either sample size or completeness of dataset is compromised.
This study is funded by the Medical Research Council. The grant reference number is MR/W021560/1

Start Date01 Dec 2026

Sponsor / Collaborator

University of Oxford

NCT06349122

/ Not yet recruitingPhase 3IIT

Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth: A Multicentre, Randomized Study (AUTOP 2)

Preterm birth is a major cause of mortality and long-term disability. Bacterial vaginosis (BV) is a frequent form of dysbiosis that is often asymptomatic and increases the risk of preterm birth. BV is usually diagnosed using conventional tools such as the Nugent score. Molecular diagnosis of BV has now been shown to be more reproducible and to provide a more accurate characterization of dysbiosis.
The main objective of this study is to evaluate the effectiveness of a self screen and treat strategy for vaginal flora dysbiosis, based on molecular point of care (POC) multiplex technology before 18 weeks' gestation, in reducing the rate of preterm birth among pregnant women at high risk, compared with usual care.
The hypothesis is that a Screen-and-Treat strategy using molecular biology among women with previous preterm or/and an history of late abortion could be effective in reducing preterm births by 40%.

Start Date01 Oct 2026

Sponsor / Collaborator

Assistance Publique Hôpitaux de Marseille

100 Clinical Results associated with Ceftriaxone Sodium

100 Translational Medicine associated with Ceftriaxone Sodium

100 Patents (Medical) associated with Ceftriaxone Sodium

21,949

Literatures (Medical) associated with Ceftriaxone Sodium

01 Jan 2027·Journal of Clinical and Experimental Hepatology

On-demand and Shorter Duration Versus Standard-duration Antibiotic Prophylaxis in Cirrhotic Patients With Variceal Bleeding: A Systematic Review and Meta-analysis

Review

Author: Drenth, Joost P H ; Maan, Raoel ; Bot, Kimberly K I M ; Remmelzwaal, Sharon ; Lantinga, Marten A ; de Wit, Koos

Background:

The optimal duration of antibiotic prophylaxis in cirrhotic patients with variceal bleeding remains debated. Current guidelines (European Association for the Study of the Liver, American Association for the Study of Liver Disease, and Baveno VII) recommend 5-7 days of antibiotics, largely based on pre-2010 studies. While ceftriaxone reduces mortality, rebleeding, and infections, prolonged use may increase antimicrobial resistance, hospital length of stay, and costs. We evaluated whether shorter or on-demand antibiotic strategies are comparable to standard prophylaxis.

Aim:

This systematic review and meta-analysis compared standard prophylaxis (5-7 days) with shorter (<5 days) or on-demand strategies. The primary outcomes were rebleeding and bacterial infections. The secondary outcomes included length of stay, infection subtypes, bilirubin at admission, and all-cause mortality.

Results:

Thirteen studies including 2194 patients were analysed; 10 were randomised controlled trials, and three were retrospective studies. Heterogeneity was high (I ² >50%). The pooled odds ratio in favour of standard treatment strategies was 1.22 (95% confidence interval [CI]: 0.64-2.32) for rebleeding and 1.53 (95% CI 0.66-3.54) for bacterial infections. Recent studies reported lower risk estimates than earlier studies. Meta-regression showed a downward trend in infection risk over time (P ≤ 0.0001). The secondary outcomes did not differ significantly.

Conclusion:

Although pooled estimates numerically favoured standard prophylaxis, recent evidence suggests that alternative strategies may be as effective. While this generates the hypothesis that current guideline recommendations may no longer reflect modern practice, the prevailing uncertainty emphasises the need for new and adequately powered randomised trials before clinical practice can be definitively altered.

01 Jan 2027·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Case Report : Streptococcus equi subspecies zooepidemicus bacteriemia and spondylodiscitis following direct contact with a horse

Article

Author: De Rico, Luca ; Potvin, Élie

INTRODUCTION:

Streptococcus equi subspecies zooepidemicus is a zoonotic pathogen that commonly colonizes the respiratory tract and oral cavity of horses. Human infections are rare and most frequently present as bacteremia, meningitis, or pneumonia.

PATIENTS AND METHODS:

We report the case of an 88-year-old patient who developed Streptococcus equi subspecies zooepidemicus spondylodiscitis after direct and exclusive contact with a live horse. Clinical, microbiological, and radiological findings were reviewed.

RESULTS:

Blood cultures identified Streptococcus equi subspecies zooepidemicus. Magnetic resonance imaging confirmed spondylodiscitis. The patient was successfully treated with a 45-day course of intravenous ceftriaxone followed by a 10-day course of oral levofloxacin, resulting in favorable clinical evolution.

CONCLUSION:

This appears to be the first reported case of Streptococcus equi subspecies zooepidemicus spondylodiscitis associated with direct and exclusive contact with a live horse. Clinicians should inquire about horse exposure when evaluating invasive streptococcal infections.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Türkiye, 2019–2025: An update in the 10th to 15th years of routine pneumococcal conjugate vaccination

Article

Author: Karadağ Öncel, Eda ; Ay Altıntop, Yasemin ; Öz, Fatma Nur ; Güdücüoğlu, Hüseyin ; Hazırolan, Gülşen ; Hasçelik, Gülşen ; Duman, Yücel ; Koyuncu Özyurt, Özlem ; Öztürk, Candan ; Özhak Baysan, Betil ; Yılmaz, Nisel ; Emiroğlu, Melike ; Uslu, Hakan ; Özakın, Cüneyt ; Akgün Karapınar, Deniz Bahar ; Telli, Murat ; Hasdemir, Ufuk ; Çizmeci, Zeynep ; Yaman, Akgün ; Öksüz, Lütfiye ; Aydın, Faruk ; Özbek, Özgen Alpay ; Karbuz, Adem ; Devrim, İlker ; Zer, Yasemin ; Birinci, Asuman ; Öcal, Duygu ; Dinleyici, Ener Çağrı ; Sorguç, Yelda ; Aydemir, Sabire Şöhret ; Özkaya, Esra ; Ceyhan, Mehmet ; Kara, Soner Sertan ; Akpolat, Nezahat

Invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae remains a significant cause of pediatric morbidity. This study updates the serotype distribution and antibiotic resistance of pediatric IPD in Türkiye for 2019-2025, about a decade after 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in the National Immunization Program. We conducted a multicenter, hospital-based prospective surveillance between January 2019-April 2025 in children <18 y across 28 tertiary hospitals. S. pneumoniae isolates from sterile sites (blood, cerebrospinal fluid, pleural fluid) were confirmed by standard methods and serotyped using the Quellung reaction. Antimicrobial susceptibility was determined by gradient test as per CLSI criteria. A total of 203 samples were identified from 203 pediatric cases (median age 4 y, 56.2% boys). The clinical presentations were bacteremia/sepsis (57.6%) and meningitis (26.1%). The leading serotypes were 3 (14.3%), 14 (10.3%), 19F (7.9%), 19A (6.4%), 9N (4.4%), 15A (4.4%). PCV13 serotypes accounted for 46.8% isolates, while PCV7 and PCV10 serotypes were detected in 23.2% and 24.6%, respectively. Broader vaccines would increase coverage: PCV15 (46.8%) and PCV20 (56.7%). Antibiotic susceptibility (non-meningitis breakpoint) remained high for beta-lactams; 91.9% of isolates were penicillin-susceptible, with only 0.7% fully resistant, and cefotaxime resistance was rare (2.7%). Conversely, macrolide resistance was high, with 60.2% of isolates resistant to erythromycin. A decade after PCV13 implementation, vaccine serotypes - particularly 3, 14, 19F, and 19A - still cause nearly half of pediatric IPD, though non-vaccine serotypes such as 9N and 15A are rising. Higher-valent PCVs may improve protection, and continued surveillance is critical to guide vaccine policy and treatment strategies.

101

News (Medical) associated with Ceftriaxone Sodium

24 Jun 2026

·www.scripps.edu

Back in action: Researchers make drug-resistant bacteria vulnerable again

New findings from Scripps Research show that disabling a single bacterial protein can restore vancomycin’s power against resistant bacteria–and point to a new strategy for overcoming antibiotic resistance. June 24, 2026 LA JOLLA, CA—Antibiotic resistance is one of the most urgent threats to global health, linked to an estimated 4.7 million deaths worldwide in 2019 alone. As more bacteria evolve to evade even last-resort drugs, the supply of effective treatments is shrinking. Now, scientists at Scripps Research have discovered a way to restore the effect of one of those critical antibiotics by disabling a key bacterial enzyme. The study, published in Nature Communications on June 16, 2026, focused on vancomycin-resistant Enterococcus faecium, or VREfm, a hospital-acquired infection that is becoming increasingly common. VREfm can resist multiple antibiotics held in reserve for the toughest infections, including its namesake, vancomycin, a potent drug often used to treat life-threatening infections. The researchers wanted to know whether disabling a specific bacterial enzyme called secreted antigen A (SagA) could make VREfm vulnerable to vancomycin again, rendering it treatable without needing a new antibiotic. SagA is found across a wide range of VRE strains, making it an attractive target for therapies designed to work broadly against resistant infections. When the researchers genetically deleted the enzyme from VREfm, the bacteria became markedly more susceptible to vancomycin. “The SagA enzyme remodels the cell wall so that bacteria divide properly,” says senior author Howard Hang, a professor at Scripps Research. “If you disrupt that, the bacteria don’t divide as well, and it makes the bacteria more sensitive to vancomycin.” There was already evidence that genetic deletion of the enzyme makes the bacteria more vulnerable to antibiotics, says Hang. “But the fact that it sensitizes the cells to vancomycin, when the bacteria are already resistant to it, was a surprise.” Deleting SagA had little impact on the bacteria's resistance to other antibiotics such as ampicillin, daptomycin and ceftriaxone. This suggested that the deletion wasn’t just making the bacteria frailer overall, but was specifically exposing the site where vancomycin binds. The strategy also worked in a mouse model of sepsis. The researchers also screened a large chemical library and identified a class of compounds called β-chloroalkenyl sulfonyl fluorides that chemically disable SagA. Their lead compound, called pghi-4, reduced the amount of vancomycin needed to kill VREfm by up to 8-fold when the two were combined. The effect held up across multiple clinical isolates and reduced the bacterial burden in infected mice. SagA belongs to a family of cell-wall-remodeling enzymes called NlpC/P60 peptidoglycan hydrolases that no drug had ever successfully targeted before. “To demonstrate you can pharmacologically target this enzyme family is a big step forward,” says Hang. The approach is part of a promising category of treatments known as antibiotic adjuvants: compounds that aren’t antibiotics themselves but help existing antibiotics work better against resistant bacteria. Proven adjuvants already exist for a narrow range of drugs, but this is the first such helper developed for vancomycin. The study data suggest that pghi-4 and related compounds may target other peptidoglycan-remodeling enzymes beyond SagA. That raises the possibility that bacteria carrying extra copies of SagA-like enzymes could be more vulnerable to this approach, which is significant because VREfm strains tend to carry more of these enzymes. “This is a promising new weapon in the ongoing arms race against antibiotic resistance,” says Hang. The broader lesson, he adds, is that targeting basic aspects of bacterial physiology can overcome antibiotic resistance. The researchers are already working on more potent second-generation derivatives that couple the existing compound with vancomycin. They believe the same strategy could eventually be extended to other combinations of resistant bacteria and antibiotics, including pathogens such as tuberculosis and drug-resistant Staphylococcus aureus. In addition to Hang, authors of the study “Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant Enterococcus faecium” include Kyong T. Fam, Pavan Kumar Chodisetti, Adrianna M. Turner, Seiya Kitamura, Benjamin Silva, Yijun Xiong, Althea Hansel-Harris, Matthew Holcomb, Simeon Babarinde, Ian A. Wilson, Stefano Forli, Benjamin F. Cravatt, Donghyun Park, and Dennis W. Wolan of Scripps Research; Zifei Wang, Joshua A. Homer, and John E. Moses of Cold Spring Harbor Laboratory; Christopher J. Smedley of La Trobe University; and Daria Van Tyne of the University of Pittsburgh School of Medicine. This work was supported by the National Institutes of Health (grant R21AT012958) and Scripps Research start-up funds, with additional support from the Cold Spring Harbor Laboratory NCI Cancer Center Support Grant (5P30CA045508), the Australian Research Council (FT170100156), and the F.M. Kirby Foundation For more information, contact press@scripps.edu See More News

20 May 2026

·www.einpresswire.com

iRemedy Releases AI-Powered Foreign Dependency Assessment of America’s Essential Medicines

Analysis of all 84 ASPR-designated essential medicines finds 89% show significant Chinese supply chain dependency across four layers of origin verification The policy conversation has focused on whether we are dependent on China for critical medicines. This assessment answers that question with data, medicine by medicine.” — Tony Paquin, CEO, iRemedy Healthcare STUART, FL, UNITED STATES, May 20, 2026 / EINPresswire.com / -- iRemedy Healthcare Companies, Inc. today released the Foreign Dependency Assessment, an AI-powered analysis of all 84 medicines on the federal ASPR Essential Medicines List. Produced by TheTradeSpy.ai, iRemedy’s autonomous supply chain intelligence platform, the assessment traces each medicine through four progressive layers of manufacturing dependency. The central finding: 75 of 84 medicines, 89.3% of the list, show significant dependency on China at one or more supply chain tiers. The release comes as U.S. pharmaceutical supply chain security has drawn increased legislative and regulatory attention. The BIOSECURE Act passed the Senate in December. The FDA continues to track active shortages of essential medicines. The Foreign Dependency Assessment provides the first medicine-by-medicine mapping of Chinese supply chain exposure across the full ASPR essential medicines list. The full report is publicly available at https://iremedy.com/essential-medicines . Key Findings The assessment documents a pattern in which country-of-origin labels on essential medicines frequently do not reflect the ultimate source of active pharmaceutical ingredients or key starting materials. Norway, Portugal, Morocco, Mexico, and India appear repeatedly as U.S. suppliers of essential medicines but function primarily as last-step processors of material originating elsewhere in the supply chain. The analysis further identifies that 31 of the 84 essential medicines have at least one U.S.-marketed product whose labeler is linked to a Chinese state-affiliated manufacturer, including instances where parent-company ownership structures are not reflected in standard procurement databases. In the case of heparin, a critical anticoagulant used in surgical care and dialysis, the assessment identifies a specific parent-company ownership linkage that iRemedy has characterized as an actionable data-quality finding for federal procurement authorities. “What this data shows is fraud, plain and simple,” said Tony Paquin , Founder and CEO of iRemedy Healthcare Companies. “The American people are being told their medicines come from trusted, diversified sources. They don’t. When you follow the chemistry back to its origin, not the label, but the actual raw material, you find China at the base of nearly every chain, with ownership structures deliberately designed to keep that fact hidden. Patients, hospitals, and the U.S. government are paying for transparency they are not receiving.” About the Methodology The assessment was produced by TheTradeSpy.ai, which deploys 31 specialized AI agents across more than 129,000 National Drug Codes. The platform synthesizes bills of lading, UN Comtrade data, FDA regulatory filings, and corporate ownership records, tracing each medicine through four measurement layers: direct U.S. import flows, supplier-country import flows, key starting material precursor flows, and peer-reviewed literature attribution. Risk is scored using a deterministic 63-factor model producing a Made-in-America confidence score at the NDC level. All percentages are reported as conservative lower-bound estimates by physical weight. Every determination carries its source, its timestamp, and its confidence tier. Summary Statistics • 89.3% of ASPR essential medicines (75 of 84) show significant Chinese dependency at one or more supply chain tiers. • 36.9% (31 of 84) have at least one U.S.-marketed product linked to a Chinese state-affiliated manufacturer. • 85%+ of the nucleus compounds for the beta-lactam antibiotic family, including amoxicillin and ceftriaxone, are attributed to Chinese origin, a dependency not reflected in finished-product country-of-origin labeling. • 9 of 84 medicines were found to be structurally independent of Chinese supply chain dependency. “The policy conversation has focused on whether we are dependent on China for critical medicines,” Paquin added. “This assessment answers that question with data, medicine by medicine. We built TheTradeSpy.ai specifically to make the true origin of America’s medicine supply visible, measurable, and actionable. Every government procurement officer needs the tools to see it.” About iRemedy Healthcare Companies iRemedy Healthcare Companies, Inc., based in Stuart, Florida, is a healthcare distributor and supply chain intelligence company focused on Made in America medicines and medical supplies. Over fifteen years, iRemedy has supplied more than 1.1 billion units of medical product to the Department of Defense, the Department of Veterans Affairs, and U.S. healthcare systems, protected by a portfolio of 10 issued U.S. patents on AI-driven supply chain automation. Learn more at iremedy.com. About TheTradeSpy.ai TheTradeSpy.ai is iRemedy’s autonomous supply chain intelligence platform, tracking more than 129,000 National Drug Codes via 31 AI agents and a deterministic 63-factor scoring model. The platform is available to federal agencies, healthcare systems, and qualified strategic partners. Learn more and request a briefing at TheTradeSpy.ai. Sakshee Sharmaa iRemedy Marketing@iremedy.com Visit us on social media: LinkedIn Instagram Facebook YouTube X Other Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

20 Apr 2026

·www.biospace.com

Fedora Pharmaceuticals Presentations at 2026 ESCMID Highlight Safety and Potent Bactericidal Activity of FPI-2119

Potent antibacterial activity against Gram-negative community and hospital-acquired infections highlighted across eight posters and two presentationS EDMONTON, Alberta , April 19, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. , a leader in the development of drugs to treat antibiotic-resistant infections, is presenting a full suite of preclinical findings from the company’s lead candidate, FPI-2119 at the European Society of Clinical Microbiology and Infectious Diseases Congress (ESCMID) in Munich, Germany. Presentations at ESCMID are authored by Fedora as well as collaborators at St. Jude Children’s Research Hospital, JMI Laboratories (Part of Element), Indiana University, and Pharmacology Discovery Services (a Eurofins Discovery Partner Lab). ESCMID presentations will highlight the candidate’s activity against some of the most difficult-to-treat Gram-negative infections, including respiratory tract infections, sexually transmitted infections, and high-mortality nosocomial infections. Many of these pathogens are in the high-priority category in the World Health Organization (WHO) Bacterial Priority Pathogens List (BPPL) due to the public health challenges they present and the limited treatment options available. “For decades, the medical community has relied on antibiotics to ensure the effective treatment of both hospitalized patients and those with community-acquired infections such as urinary tract infections (UTIs),” explained Karen Bush, Ph.D. , Indiana University professor emerita and member of the Fedora scientific advisory board. “Research into new antibacterial agents is very limited in spite of the fact that pathogens continue to evolve new resistance mechanisms. Every year increasing treatment failures occur to previously reliable antibacterial agents. This puts hospital patients and the greater community at serious risk of succumbing to infections that were once easily treatable. The data being presented at ESCMID show that FPI-2119 has the potential to become a valuable tool to fight today’s infectious diseases.” Fedora’s poster presentations at ESCMID highlight the following findings from preclinical studies of FPI-2119: Concentration-dependent bactericidal activity and low frequency of resistance against Pseudomonas aeruginosa (Poster 2568) Maintenance of activity against Escherichia coli strains carrying a broad range of potent β-lactamase encoding genes, confirming its stability in the presence of this resistance mechanism (Poster 2580) Activity against a collection of bacterial isolates, including resistant strains of Campylobacter , Salmonella , and Shigella , as well as Haemophilus influenzae and Moraxella catarrhalis , which are commonly associated with intestinal and respiratory tract infections (Poster 2581) Potency against all strains of N. gonorrhoeae including six that are resistant to penicillin, tetracycline, and ciprofloxacin, three of which exhibit reduced susceptibility to ceftriaxone (Poster 2583) No measurable cardiotoxicity and clean off-target safety profile (Poster 2599) Potency at comparable or lower concentrations than cefepime to treat multidrug-resistant strains of P. aeruginosa , E. coli , and Klebsiella pneumoniae (Poster 2601) Statistically significant and dose-dependent reductions in bacterial burden in bladder and kidney in a mouse model of complicated UTI (Poster 2643) Half-life and plasma concentrations predictive of BID (twice a day) or QD (once a day) dosing in humans (Poster 2801) “Our first pipeline candidate, nacubactam, is a β-lactamase inhibitor with the potential to restore bactericidal activity to β-lactam antibiotics,” stated Christopher Micetich , chief executive officer and founder of Fedora Pharmaceuticals. “FPI-2119, our second candidate, is a potent antibiotic with the potential to treat infections caused by pathogens that produce β-lactamases. Together, these candidates offer innovative strategies to address the urgent need to treat resistant infections.” About FPI-2119 FPI-2119, a first-in-kind derivative of the lactivicin class, is in development for the treatment of Gram-negative infections. As a non-β-lactam antibiotic, FPI-2119 lacks the classical ring structure that defines that class. It is therefore not expected to be susceptible to β-lactamases, a resistance mechanism bacteria have developed to thwart β-lactam antibiotics such as cefepime. FPI-2119 has demonstrated a broad spectrum of activity against multiple Gram-negative pathogens including Pseudomonas aeruginosa , Acinetobacter baumannii , Enterobacterales, and other clinically significant pathogens. Target indications include complicated hospital-acquired and ventilator-associated bacterial pneumonia (cHABP/cVABP), complicated urinary tract infections (cUTI), and complicated intra-abdominal infections (cIAI). About Fedora Pharmaceuticals Fedora Pharmaceuticals Inc. is an innovative biotech founded in 2011 and headquartered in Edmonton, Alberta, Canada. The company is dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance (AMR). With a strong pipeline and expert scientific team, Fedora’s mission is to deliver solutions that impact global health. Fedora’s most advanced candidate is nacubactam, a Phase 3-ready β-lactamase inhibitor being advanced with partner, Meiji Seika. Fedora holds key US rights to nacubactam. Fedora is seeking development partners for nacubactam in the US. For more information, please visit . About St. Jude Children's Research Hospital St. Jude Children’s Research Hospital is leading the way the world understands, treats, and cures childhood catastrophic diseases. From cancer to life-threatening blood disorders, neurological conditions, and infectious diseases, St. Jude is dedicated to advancing cures and means of prevention through groundbreaking research and compassionate care. Through global collaborations and innovative science, St. Jude is working to ensure that every child, everywhere, has the best chance at a healthy future. To learn more, visit stjude.org , read St. Jude Progress , a digital magazine, or contact St. Jude at media@stjude.org. CONTACT: Media and Investors: info@fedorapharma.com

Phase 3Qualified Infectious Disease Product

100 Deals associated with Ceftriaxone Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D00924	Ceftriaxone Sodium	J01DD04	DB01212

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arthropathy associated with infection	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Infection of bone	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Postoperative infection	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Skin and skin structure infections	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Genitourinary tract infection	China	Shanghai Roche Pharmaceuticals Ltd.	01 Jan 1998
Lyme Disease	China	Shanghai Roche Pharmaceuticals Ltd.	01 Jan 1998
Reproductive Tract Infections	China	Shanghai Roche Pharmaceuticals Ltd.	01 Jan 1998
Respiratory Tract Infections	China	Shanghai Roche Pharmaceuticals Ltd.	01 Jan 1998
Wound Infection	China	Shanghai Roche Pharmaceuticals Ltd.	01 Jan 1998
Biliary tract infection	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Bone and joint infections	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Gonorrhea	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Infectious Diseases	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Intraabdominal Infections	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Lower Respiratory Tract Infections	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Meningitis	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Pelvic Infection	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Sepsis	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Skin structures and soft tissue infections	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Urinary Tract Infections	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infection of ear	Clinical	China	Shanghai Bao Pharmaceutical Co. Ltd.	08 Aug 2025
Nasal infection	Clinical	China	Shanghai Bao Pharmaceutical Co. Ltd.	08 Aug 2025
Peritonitis	Clinical	China	Shanghai Bao Pharmaceutical Co. Ltd.	08 Aug 2025
Pharyngitis	Clinical	China	Shanghai Bao Pharmaceutical Co. Ltd.	08 Aug 2025
Pneumonia	Clinical	China	Shanghai Bao Pharmaceutical Co. Ltd.	08 Aug 2025
HIV Infections	Clinical	United States	Hoffmann-La Roche, Inc.	31 Aug 2001
Neurosyphilis	Clinical	United States	Hoffmann-La Roche, Inc.	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05156437 (OPTIMAL, CTgov)	Phase 4	Endocarditis	5	Cefalexin+Levofloxacin+Amoxycillin+Oxacillin+Ceftriaxone+Dicloxacillin+Rifampicin+Ampicillin+Linezolid+Daptomycin+Vancomycin (Group I (Experimental))	azucvlvwso(wgxukohhhm) = jjqyrwvbxa lurdrroeyl (ebmbptbnqu, jshxcywdmi - bmxuludtal) View more	-	05 May 2026
				Oxacillin+Ceftriaxone+Ampicillin+Daptomycin+Vancomycin (Group II (Control Group))	azucvlvwso(wgxukohhhm) = weaorbzyhz lurdrroeyl (ebmbptbnqu, qvjktqygbq - vdnsrikrtc) View more
AAN2026	Not Applicable	Lyme Neuroborreliosis	90	Ceftriaxone	vjybpzsigp(zyidfielbw) = aswjodohxh bpidbozkbo (qcmncczdmj ) View more	Positive	25 Apr 2026
AAAAI2026	Not Applicable	-	86	Cefazolin	roifuqjiil(xtohhtjxyw) = ieqbjwvqqp pgfgodvytg (fhfvcekvkb ) View more	Positive	27 Feb 2026
NCT05980871 (CTgov)	Phase 4	Syphilis	109	CRO+Doxy (CRO/Doxy)	zynzojtgbg = ljtpxuqjgv uqzktxvldo (syeleelbzm, dxfibvrhqr - qepqesgwdy) View more	-	25 Feb 2026
				BPG+Doxy (BPG/Doxy)	zynzojtgbg = povaxolwky uqzktxvldo (syeleelbzm, yztvmfikam - tplzudploa) View more
EURETINA2025	Not Applicable	Uveitis	25	Intravenous Ceftriaxone + Oral Corticosteroids	eqdseceopf(pykzjmikid) = fttblcovit mvldqwpmuq (drkqrfydxi, 0.07) View more	Positive	04 Sep 2025
Literature Manual	Phase 2/3	Whipple Disease	64	oral doxycycline +hydroxychloroquine	yjysypgdww(ospzrvmltj) = prejhlrtdc eyqebbnwoe (cjogqwzpwl ) View more	Non-inferior	17 Feb 2025
				intravenous ceftriaxone+oral trimethoprim-sulfamethoxazole	yjysypgdww(ospzrvmltj) = lztoxdyvxf eyqebbnwoe (cjogqwzpwl ) View more
NCT05027516 (ResistAZM, CTgov)	Phase 4	Gonorrhea	42	Rocephin (Rocephine®)	zztjyhwxvd(cceiwwhxai) = zizwvozbis ryrhlrvdjn (magiainvhy, vettyhywei - pytgezizev) View more	-	02 Aug 2024
				Azithromycin+Rocephin (Rocephine® + Azithromycin)	jjcwlpqpas = ywejbnxdha gkbxrfuivi (xahcaobkbj, umllyktidg - nqgrqfkosa) View more
NCT02265406 (PROPHY-VAP, Pubmed \| Lancet Respir Med) Manual	Phase 3	Pneumonia, Ventilator-Associated	319	Ceftriaxone 2 g	ouqmyurdgy(eeueiqwblm) = cioqnfxmhk ckrvnxrahf (zvvpkstyaf )	Positive	19 Jan 2024
				Placebo	ouqmyurdgy(eeueiqwblm) = irpnnrfiah ckrvnxrahf (zvvpkstyaf )
NCT04218695 (Pubmed) Manual	Phase 4	Infectious Diseases	30	ceftriaxone	bglscmmnnt(xodmahnlaq) = There were no observed statistically significant differences between groups in incidence of infection, mortality, length of stay, or key laboratory parameters, including C-reactive protein and procalcitonin. xtleeeuxtw (xinbfqvzxb )	Negative	01 Jan 2024
				Placebo
NCT05149287 (PROPER, CTgov)	Phase 2	Meniscus disorder \| Inflammation \| Cartilage Injury ... View more	5	Ceftriaxone (Experimental)	ojcsuewtxw(haamcicyim) = azarudsouv igcwnchrwp (oxdsplhgwz, 1.11) View more	-	05 Sep 2023
				Placebo (Placebo)	ojcsuewtxw(haamcicyim) = irdwaqhghn igcwnchrwp (oxdsplhgwz, 2.97) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis